PMC:7309518 / 1127-1705 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":14,"end":25},"obj":"Body_part"},{"id":"T5","span":{"begin":107,"end":114},"obj":"Body_part"},{"id":"T6","span":{"begin":152,"end":165},"obj":"Body_part"},{"id":"T7","span":{"begin":170,"end":174},"obj":"Body_part"},{"id":"T8","span":{"begin":283,"end":295},"obj":"Body_part"},{"id":"T9","span":{"begin":300,"end":316},"obj":"Body_part"},{"id":"T10","span":{"begin":317,"end":328},"obj":"Body_part"},{"id":"T11","span":{"begin":470,"end":476},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma65239"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma82780"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma32558"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":311,"end":316},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"T28","span":{"begin":229,"end":239},"obj":"Disease"},{"id":"T29","span":{"begin":266,"end":274},"obj":"Disease"},{"id":"T30","span":{"begin":401,"end":409},"obj":"Disease"},{"id":"T31","span":{"begin":521,"end":529},"obj":"Disease"},{"id":"T32","span":{"begin":540,"end":543},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005244"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0009722"},{"id":"A33","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0016098"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T3","span":{"begin":170,"end":174},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":300,"end":316},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T5","span":{"begin":470,"end":476},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T6","span":{"begin":470,"end":476},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T7","span":{"begin":470,"end":476},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T8","span":{"begin":470,"end":476},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T4","span":{"begin":45,"end":49},"obj":"Chemical"},{"id":"T5","span":{"begin":107,"end":114},"obj":"Chemical"},{"id":"T6","span":{"begin":129,"end":140},"obj":"Chemical"},{"id":"T7","span":{"begin":136,"end":140},"obj":"Chemical"},{"id":"T8","span":{"begin":152,"end":165},"obj":"Chemical"},{"id":"T9","span":{"begin":190,"end":194},"obj":"Chemical"},{"id":"T10","span":{"begin":283,"end":295},"obj":"Chemical"},{"id":"T11","span":{"begin":317,"end":328},"obj":"Chemical"},{"id":"T12","span":{"begin":353,"end":361},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_28175"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_26667"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_28175"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_16919"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PubTator","denotations":[{"id":"49","span":{"begin":353,"end":368},"obj":"Gene"},{"id":"52","span":{"begin":419,"end":427},"obj":"Species"},{"id":"53","span":{"begin":438,"end":446},"obj":"Species"},{"id":"54","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"55","span":{"begin":129,"end":140},"obj":"Chemical"},{"id":"56","span":{"begin":283,"end":295},"obj":"Chemical"},{"id":"57","span":{"begin":317,"end":328},"obj":"Chemical"},{"id":"69","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"70","span":{"begin":222,"end":239},"obj":"Disease"},{"id":"71","span":{"begin":266,"end":274},"obj":"Disease"},{"id":"72","span":{"begin":401,"end":418},"obj":"Disease"},{"id":"73","span":{"begin":462,"end":485},"obj":"Disease"},{"id":"74","span":{"begin":521,"end":529},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Gene:51727"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:9606"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D005732"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D019158"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D005732"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D006017"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:C000657245"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D001039"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D018908"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-sentences","denotations":[{"id":"T14","span":{"begin":344,"end":568},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":45,"end":49},"obj":"GlycoEpitope"},{"id":"T2","span":{"begin":185,"end":194},"obj":"GlycoEpitope"},{"id":"T3","span":{"begin":190,"end":194},"obj":"GlycoEpitope"}],"attributes":[{"id":"A1","pred":"glyco_epitope_db_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0059"},{"id":"A2","pred":"glyco_epitope_db_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/AN0403"},{"id":"A3","pred":"glyco_epitope_db_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0059"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":229,"end":239},"obj":"Phenotype"},{"id":"T12","span":{"begin":344,"end":368},"obj":"Phenotype"},{"id":"T13","span":{"begin":470,"end":485},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0009830"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0003236"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0001324"}],"text":"her Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of "}